Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH

Corvus Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.62

Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).
Cash, equivalents & securities $49.6M at Sep 30, 2022; projected year-end $40.5-42.5M.
CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR; new data at ASH Dec 2022.
Ciforadenant Phase 1b/2 in first-line RCC initiated with KCRC; up to 60 patients.
IND approved in China for mupadolimab Phase 1/1b combo with pembrolizumab in lung/head & neck cancers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Corvus Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.